Navigation Links
Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Date:4/29/2013

ROCKVILLE, Md., April 29, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that final data on the intraspinal delivery method employed in its NSI-566 Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) was presented today at the American Association of Neurological Surgeons Annual Meeting. In a presentation called "Intraspinal Stem Cell Transplantation in ALS, A Phase I Trial: Cervical Microinjection Safety Outcomes," Jonathan Patrick Riley , MD, of the Department of Neurological Surgery at Emory University, in Atlanta, GA, presented data from all 18 procedures, in 15 patients, treated in Phase I. (Three of the patients returned to the trial for subsequent treatments in a different region of the spinal cord.) The study found that none of the patients experienced neurological worsening from injections into either the upper (cervical) or lower (lumbar) region of the back, nor was there any evidence of spinal cord injury. The cells also appeared to be safe with no evidence of toxicity. Researchers further noted that, even in the vulnerable ALS spinal cord, serial injections were well-tolerated. They concluded that the approach of starting in the lower region of the spine, where the potential risk to the patient was less, and then progressing upwards, might not be required in future trials, and that this intraspinal delivery technique is an option for treating other neurodegenerative and traumatic spinal cord disorders.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"This is an extremely important confirmation of the safety and tolerability of both the route of administration and our cells," said Karl Johe , PhD, Neuralstem Chairman and Chief Scientific Officer and a stu
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
2. Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
3. Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
4. Neuralstem Secures $8 Million In Debt Financing From Hercules
5. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
6. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
7. Neuralstem to Raise $7.0 Million in Registered Direct Offering
8. Neuralstem Announces Proposed Public Offering
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
11. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Columbia Laboratories, Inc. (Nasdaq: ... today announced financial results for the three and ... "Second quarter results benefited from the contribution ... diversified revenue stream partially offset an anticipated and ... during a routine license renewal in one high-volume, ...
(Date:7/31/2014)... 31, 2014 Marken announced today the expansion ... meet the clinical trial logistics growth in Central and ... facility will continue to serve as a regional center ... from the region, and will provide additional storage capacity. ... combine its office and warehouse into a single facility, ...
(Date:7/31/2014)... , July 31, 2014 ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... Report. Diabetes, growing at an exponential rate ... has emerged as a major cause of death of ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Marken Expands Miami Regional Logistics Center 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 3The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 4The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 5The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 6The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 7The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 8
... Electronics, Inc. (NYSE: BHE ), a leading ... it helped commercialize and currently manufactures has won the ... for best new science and medical diagnostic product. ... 2011 Medical Design Excellence Award in the In Vitro ...
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... and CEO will deliver a corporate presentation on Thursday, ... The presentation will take place as part of the ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner 2
(Date:7/31/2014)... bill introduced in Congress with bipartisan support would allow ... Michigan research, which could improve the health of patients ... the medicines and tests they need most. , The ... and Earl Blumenauer, grew out of a decade of ... Institute for Healthcare Policy and Innovation. It would allow ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of cancer ... Heat-Shock Factor 1 (HSF1) can also turn neighboring ... malignant progression and metastasis. , The finding, reported ... journal Cell , lends new insights into ... prognosis, and management of cancer patients. , ...
(Date:7/31/2014)... 31, 2014 The North America Phytochemicals & ... plant extracts market in North America with analysis and forecast ... around $576.3 million in 2012 to $930.1 million by 2018, ... Browse through the TOC of the North America phytochemicals & ... in-depth analysis provided. It also provides a glimpse of the ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 ... publication dedicated to delivering cutting-edge information focused ... and therapeutics, recently launched its newly designed ... website optimizes navigation by providing visitors specialized ... analytical and strategic business areas. As the ...
Breaking Medicine News(10 mins):Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:BioProcess International Launches New Website 2
... and observational studies show an increased risk for cancer ... problem may be worse than currently known. ... going to see the current disparity in knowledge and ... director of the Institute for Health Promotion Research at ...
... Researchers at the University of Alabama at Birmingham ... four biomarkers that will help predict which patients are ... are not. The findings also shed light on the ... African-Americans, compared with Caucasians, the researchers said. In ...
... John Theurer Cancer Center at Hackensack University Medical Center ... patients on Friday, April 23 and Saturday, April 24. ... Management of Hematological Malignancies", is part of John Theurer ... well as patients with an update on the newest ...
... heart problems that stems from a genetic defect in the ... protein,s function can lead to cardiac arrest, which is exactly ... investigation at Sahlgrenska University Hospital at the University of Gothenburg, ... today in the revered New England Journal of Medicine ...
... ... release of their new title in the Tarascon Pocketbook series, Tarascon Global Health Pocketbook, ... portable guide provides regional and issue-based information on international medicine throughout the world. ... Sudbury, MA (Vocus) ...
... Study found infection rates highest among black children in ... -- Treatment-resistant ringworm is common among urban elementary school ... in kindergarten through Grade 5 at 44 schools across ... 6.6 percent of them were infected with the fungus ...
Cached Medicine News:Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 2Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 3Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 4Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 5Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 6Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 7Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 3Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 4Health News:New explanation for cardiac arrest 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 3Health News:Resistant Ringworm Common in Urban Elementary Schools 2
... Implants are comprised only of synthetic, medical ... designed to support soft tissue ingrowth. Ocu-pore ... sizes. The material is manufactured using a ... produce a highly porous, fully interconnected, biocompatible ...
Straight iris forceps. Insulated....
Bayonet forceps....
Semkin forceps with stops. Insulated....
Medicine Products: